# Theradaptive

> Theradaptive is a clinical-stage biotech in Frederick, Maryland that re-engineers therapeutic proteins so they bind to materials and stay exactly where a surgeon places them. Its lead protein, AMP2, is a material-binding variant of the bone-growth protein rhBMP-2; combined with an implantable scaffold it becomes OsteoAdapt, a regenerative product being tested in spinal fusion, dental, and orthopedic procedures. Founded by MIT-trained Army veteran Luis Alvarez after seeing battlefield injuries, the company aims to make biologics safer by keeping them on-target.

- **Founded:** 2016
- **Headquarters:** Frederick, Maryland, United States
- **Founders:** Luis Alvarez (Founder & CEO)
- **Team size:** ~33 employees
- **Products:** AMP2, OsteoAdapt SP, OsteoAdapt DE, Targeted therapeutic delivery platform
- **Notable:** Three FDA Breakthrough Device designations for OsteoAdapt across spinal indications (2021-2022), FDA approval to advance the OASIS trial to a pivotal study for OsteoAdapt SP in spinal fusion, Treated first patient in the RESTORE dental feasibility study (2025)

## Products & services

- **AMP2** — A proprietary material-binding variant of the bone-growth protein rhBMP-2, engineered to drive potent, localized bone formation while reducing the off-target effects associated with standard rhBMP-2.
- **OsteoAdapt SP** — A regenerative bone-graft product combining AMP2 with an implantable scaffold for spinal fusion. Granted FDA Breakthrough Device designations and advancing into a pivotal (OASIS) clinical trial.
- **OsteoAdapt DE** — A next-generation regenerative product for dental procedures such as alveolar ridge augmentation, evaluated in the RESTORE feasibility study after treating its first patient in 2025.
- **Targeted therapeutic delivery platform** — A computational and protein-engineering platform that gives biologics affinity for specific implant materials, enabling long-term local delivery across orthopedics, dental, soft tissue, vascular repair, and immuno-oncology.

## Achievements

- Three FDA Breakthrough Device designations for OsteoAdapt across spinal indications (2021-2022)
- FDA approval to advance the OASIS trial to a pivotal study for OsteoAdapt SP in spinal fusion
- Treated first patient in the RESTORE dental feasibility study (2025)
- Preclinical data showing AMP2 outperformed the spinal-fusion standard of care
- Closed a $26M Series A and surpassed $43M total funding
- Awarded a ~$4M U.S. Department of Defense contract (2025)

## Latest updates

- **2026-04** — FDA granted approval to initiate the pivotal clinical trial evaluating OsteoAdapt SP for spinal fusion.
- **2026-01** — Entered a strategic partnership with ATEC and launched a Series B investment round.
- **2025-08** — Treated first patient in the RESTORE feasibility study evaluating OsteoAdapt DE in dental procedures.
- **2025-07** — Landed a ~$4M U.S. Department of Defense contract.

## Links

- Website: https://theradaptive.com
- LinkedIn: https://www.linkedin.com/company/theradaptive
- Twitter/X: https://twitter.com/theradaptive

---

Profile page: https://yespress.io/theradaptive
Published by YesPress — https://yespress.io
Last updated: 2026-06-08